Matches in Wikidata for { <http://www.wikidata.org/entity/Q65368582> ?p ?o ?g. }
Showing items 1 to 41 of
41
with 100 items per page.
- Q65368582 description "clinical trial" @default.
- Q65368582 description "ensayu clínicu" @default.
- Q65368582 description "klinisch onderzoek" @default.
- Q65368582 description "клінічне випробування" @default.
- Q65368582 name "Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors" @default.
- Q65368582 name "Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors" @default.
- Q65368582 type Item @default.
- Q65368582 label "Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors" @default.
- Q65368582 label "Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors" @default.
- Q65368582 prefLabel "Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors" @default.
- Q65368582 prefLabel "Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors" @default.
- Q65368582 P1132 Q65368582-66E40D72-B2F4-428D-A65D-AD50D6FC1E11 @default.
- Q65368582 P1476 Q65368582-E8B4ABF0-D23A-48A1-8030-5A000590F166 @default.
- Q65368582 P17 Q65368582-48CD47F3-3D31-4A93-932A-C3785C86D153 @default.
- Q65368582 P17 Q65368582-629150DE-41E1-4055-BBBD-3008C47EAEB4 @default.
- Q65368582 P17 Q65368582-E54D31D5-4915-44C6-986E-760044159E93 @default.
- Q65368582 P2899 Q65368582-82104369-F664-44BE-A361-AA9566FFCFF4 @default.
- Q65368582 P3098 Q65368582-13F1FC26-CF30-487E-9D3A-8472D791D17B @default.
- Q65368582 P31 Q65368582-B4FB65CA-60AD-495A-9EA6-A9370FB427F8 @default.
- Q65368582 P4135 Q65368582-6D01DF4F-649F-415E-B830-02F1929CBD74 @default.
- Q65368582 P4844 Q65368582-4E913F0A-26F6-4B4E-8E89-A561197CEBC5 @default.
- Q65368582 P4844 Q65368582-6B94FE65-9D0E-4A5E-B4FD-344D1875A3E2 @default.
- Q65368582 P580 Q65368582-274AD247-DCEF-4A98-A804-E7417C68121C @default.
- Q65368582 P582 Q65368582-12471935-24F4-438A-9E22-487BD41D3757 @default.
- Q65368582 P6099 Q65368582-D0274765-9A11-475D-AB0C-43A6481CBC27 @default.
- Q65368582 P8363 Q65368582-10A3BA2F-F212-4FB3-A6BF-5E2F3DAA652C @default.
- Q65368582 P1132 "+69" @default.
- Q65368582 P1476 "Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination With Weekly Paclitaxel, With or Without Bevacizumab, in Patients With Selected Advanced Solid Tumors" @default.
- Q65368582 P17 Q29 @default.
- Q65368582 P17 Q30 @default.
- Q65368582 P17 Q39 @default.
- Q65368582 P2899 "+18" @default.
- Q65368582 P3098 "NCT01831089" @default.
- Q65368582 P31 Q30612 @default.
- Q65368582 P4135 "+75" @default.
- Q65368582 P4844 Q413299 @default.
- Q65368582 P4844 Q423762 @default.
- Q65368582 P580 "2013-09-01T00:00:00Z" @default.
- Q65368582 P582 "2016-07-01T00:00:00Z" @default.
- Q65368582 P6099 Q5452194 @default.
- Q65368582 P8363 Q78089383 @default.